We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

FARN Faron Pharmaceuticals Oy

14.00 (5.38%)
01 Dec 2023 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Faron Pharmaceuticals Oy LSE:FARN London Ordinary Share FI4000153309 ORD NPV (DI)
  Price Change % Change Share Price Shares Traded Last Trade
  14.00 5.38% 274.00 20,699 16:35:14
Bid Price Offer Price High Price Low Price Open Price
250.00 270.00 260.00 260.00 260.00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations EUR EUR -28.73M EUR -0.4177 -6.22 178.85M
Last Trade Time Trade Type Trade Size Trade Price Currency
16:35:14 UT 5,407 274.00 GBX

Faron Pharmaceuticals Oy (FARN) Latest News

Faron Pharmaceuticals Oy (FARN) Discussions and Chat

Faron Pharmaceuticals Oy Forums and Chat

Date Time Title Posts
04/8/202322:32Respite for ARDS sufferers1,599

Add a New Thread

Faron Pharmaceuticals Oy (FARN) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2023-12-01 16:35:14274.005,40714,815.18UT
2023-12-01 12:03:33254.00280711.20O
2023-12-01 10:00:33268.005,00013,400.00O

Faron Pharmaceuticals Oy (FARN) Top Chat Posts

Top Posts
Posted at 02/12/2023 08:20 by Faron Pharmaceuticals Oy Daily Update
Faron Pharmaceuticals Oy is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker FARN. The last closing price for Faron Pharmaceuticals Oy was 260p.
Faron Pharmaceuticals Oy currently has 68,786,699 shares in issue. The market capitalisation of Faron Pharmaceuticals Oy is £178,845,417.
Faron Pharmaceuticals Oy has a price to earnings ratio (PE ratio) of -6.22.
This morning FARN shares opened at 260p
Posted at 23/4/2022 17:56 by share23
Faron latest presentation. CFO mentions that they have hired new VP of investor relations to New York and that they are making Faron Wallstreet ready. Are they getting ready for an IPO to Nasdaq, New York? (around 4:00 minutes)Additionally CEO talks about potential licensing deal for Bexmarilimab and refers to other deals that have been made in the area which are billion-dollar milestone deals. CEO also says after mentioning the billion dollar deals: Happy to say there are number of companies discussing with us (around 19:00 minutes).Can't believe this company is so under the radar with so low share price.
Posted at 17/11/2020 12:33 by sharesoc
The presentation packs and recording from our webinar with Faron Pharma on 3rd Nov can be found here for full members to view:

To access the presentation, you'll need to be a full member of ShareSoc, which is a not-for-profit organisation that supports individual shareholders and campaigns for shareholder rights. If you're not already a member you can join here: hxxps://

Once you've joined, you'll receive an invitation to register for our "members network" private social network, from where you'll be able to access the presentation (and presentations on 100s of other meetings). If you're already a member and have any difficulty accessing the report, please do not hesitate to contact us here: hxxps://
Posted at 25/10/2020 13:29 by sharesoc
Potential investors and current shareholders may be interested in our webinar with Faron Pharmaceuticals (FARN), 3 November 2020
Posted at 16/10/2020 09:59 by toffeeman
This is Farn IV I think

“ Solidarity’s “most disappointing results,” however, are those for interferon-beta, says Topol. Mortality among the 2050 people who received that drug (either alone or in combination with lopinavir/ritonavir) was 11.9%, versus 10.5% in the control group".
Posted at 28/9/2020 08:45 by raldo
Interesting price action today - volume picking up a bit
Posted at 24/7/2020 08:24 by ih_752952
DNL =3x Approvals expected during next 2 months including an Orphan Drug with FDA decision on September 29 = CHEAPEST UK Biotech a potential 500%++ GEM

Diurnal Group (DNL) = MCap £38 M / Cash £15 M or enough untill early 2022 / LOTS of BIG milestones on the way = Still the MOST attractive and CHEAPEST pharma stock in UK has potential to run toward 200p very fast especially on approval of Alkindi in USA (expected in September) and Chronocort in Europe (expected in Q1 ) =STRONG BUY AGGRESSIVE a sleeping giant here .GL

Market Cap £38 million
Cash £15 million
Price 30p

Alkindi approval in Australia expected this Quarter
Alkindi approval in Israel expected this Quarter
FDA decision for Alkindi on September 29
EMA Decision for Chronocort expected in early Q1 2021
Posted at 20/7/2020 16:16 by diversification
They did say that, but was that an opinion or stated fact backed up with trial results? I'm not looking to argue with you, I also managed to financially benefit from the rise in SNG, but the conference call was less than impressive imo. Good luck with your investment, I assume you also hold FARN to be positing here?
Posted at 04/5/2020 15:32 by timberwolf3
Strange that it's so quiet here considering what they potentially have, i assume it will not be long before FARN is in the spotlight.
Posted at 04/5/2020 13:32 by toffeeman
hash - it's completely different FARN is an injectible SNG is nebulised

(I hold both)
Posted at 20/2/2020 11:59 by bioking
DNL about to explode , Institutional investor added 1 million shares this week . LOTS of BIG NEWS around the corner =10+ BAGGER GEM RALLLYYYYYYYYYYYY

Diurnal (DNL)
Market Cap £27 M
Price: 31p

Upcoming Catalysts:

MAA-Acceptance for Chronocort in February/March 2020

Alkindi approval in Israel expected in 2Q 2020

Alkindi approval in Australien expected in 2Q 2020

US-Partnership for Alkindi & Chronocort expected in 1H 2020

Alkindi & Chronocort Partnership for Asia für Japan und China

US-Approval for Alkindi expected in 4Q 2020

EU Approval for Chronocort expected in 4Q/1Q 2020/21

Investment summary:Alkindi, a cortisol replacement therapy designed for children under 18 years of age, is DNL’s first product on the market. It is expected to be followed by Chronocort for adults – a larger market – which now has a clear pathway for regulatory approval in both Europe and the US. Despite this, the share price is still languishing well below valuations determined by peer group and DCF (202p) analyses
Faron Pharmaceuticals Oy share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |